Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 11/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994865 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAL3MBTL1HSD17B10ALDH1A1 | |
| SCHEMBL4990259 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAL3MBTL1HSD17B10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5593739 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAL3MBTL1HSD17B10ALDH1A1 | |
| SCHEMBL28259387 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAL3MBTL1HSD17B10ALDH1A1 | |
| SCHEMBL6656395 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAL3MBTL1HSD17B10ALDH1A1 | |
| SCHEMBL6656396 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAL3MBTL1HSD17B10ALDH1A1 | |
| SCHEMBL8971348 | 0.81 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAL3MBTL1HSD17B10ALDH1A1 | |
| SCHEMBL8971352 | 0.81 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAL3MBTL1HSD17B10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5593857 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNAL3MBTL1HSD17B10ALDH1A1 | |
| SCHEMBL11102007 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAACEABCB11USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044010-B1 | NEW PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INIHIBITORS AND THE USE THEREOF | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDO RESZVENYTARSASAG (HU) | 2014-01-08 | — | — | EP | disclosed |
| US-7960558-B2 | Pharmaceutical intermediate for synthesizing ACE inhibitors and the use thereof | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2011-06-14 | — | — | US | disclosed |
| US-20100286404-A1 | PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INHIBITORS AND THE USE THEREOF | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286404-A1 | PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INHIBITORS AND THE USE THEREOF | ACE, AGTR1, REN | SMN1; SMN2 4385/4885LMNA 2592/4885L3MBTL1 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.